Gameto Secures $33 Million in Funding to Revolutionize Female Reproductive Health

Gameto is thrilled to announce the successful completion of a $33 million fundraising round, a pivotal milestone that will significantly accelerate our mission to transform female reproductive health. As a pioneering biotechnology company, Gameto is dedicated to developing innovative therapies that address the vast unmet needs in women's health, an area that has long been overlooked in terms of effective treatment options. With this new capital, we aim to further enhance our cutting-edge platform, which utilizes advanced cellular engineering to produce female reproductive cell lines that replicate the functions of natural cells. This funding will allow us to expedite the development of our lead program, Fertilo, a revolutionary therapeutic designed to improve the IVF and egg freezing process by making it safer, shorter, and more effective. Additionally, this round will support the progression of our other groundbreaking initiatives, including Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy targeting the health challenges associated with primary ovarian insufficiency and menopause. With the backing of our investors, Gameto is positioned to make significant strides in creating better solutions for women’s health, ultimately improving the lives of countless patients who are seeking effective and safe treatments. The future of female reproductive health is bright, and we are proud to lead the way with innovative biotechnology that prioritizes the well-being of women everywhere.